Florent Gros
Managing Director @ Novartis Venture Fund
Basel, Switzerland
Florent Gros is a Series B investor at Novartis Venture Fund in Basel focused on Health Care and Biotechnology. Florent Gros is the Chairman & Founder at Amyl Therapeutics. He attended University of Mulhouse.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Florent Gros invests in
Stages Florent Gros invests in
Countries Florent Gros invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Therapeutics 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Series B 1 (50%)
- Series C 1 (50%)
Country
- France 1 (50%)
- Ireland 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Drug development firm focused on immunology. They are headquartered in Dublin, Ireland. Opsona Therapeutics is one of Europe's most innovative and dynamic drug development companies. We are at the forefront of drug development in immunology research, with particular focus on the innate immunity pathways. Since its founding in 2004,Opsona has validated and developed a series of exciting new drug candidates and strategies which modulate the human innate immune system. We are located in Dublin, Ireland. | $3.3M / Series C / Oct 02, 2013 | ||
| Myopowers Medical Technologies is a French medical device company that develops innovative technologies to provide muscle assistance to patients with high unmet medical needs. The technology can be applied to a number of indications in the GI, cardiology or urology area.The company focus is the development of ARTUS, a new and unique implantabledevice for the treatment of stress urinary incontinence. Stress urinary incontinence is a condition that affects millions of people around the world. Unfortunately, currently available products are old with significant limitations such as tissue erosion, infection or mechanical failure leading frequent re-operation.ARTUS is made of smooth and flat silicon cuff placed around the urethra. It is individually actionable and adjustable with a remote control allowing patients easy voiding and the surgeon monitoring and adjusting the cuff. This device is the first artificial urinary system specifically designed to include the treatment of female patients who account for a vast majority of the urinary incontinence market. | $16M / Series B / Jul 05, 2011 |
Co-Investors
About Novartis Venture Fund
Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, managementand board experience, and capital efficiency in the program.Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.
Novartis Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aaron Nelson
Principal & Managing Director
|
|||
Lauren Silverman
Managing Director
|
|||
Anja König
Global Head Novartis Venture Fund
|
|||
Bart Dzikowski
Managing Director, Head of Transactions & Legal
|
|||
|
Florent Gros
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Florent Gros invest in?
Florent Gros invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Florent Gros?
Public channels for Florent Gros include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Florent Gros last invest?
The most recent investment recorded for Florent Gros closed in Oct 2013. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
